A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients ; volume:41 ; number:9 ; day:12 ; month:7 ; year:2024 ; pages:3539-3556 ; date:9.2024
Advances in therapy ; 41, Heft 9 (12.7.2024), 3539-3556, 9.2024
- Urheber
-
Tamiya, Motohiro
Iwasawa, Shunichiro
Sasaki, Yusuke
Tajima, Kosei
Chiba, Yasutaka
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02905-x
- URN
-
urn:nbn:de:101:1-2411130727382.716976032685
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tamiya, Motohiro
- Iwasawa, Shunichiro
- Sasaki, Yusuke
- Tajima, Kosei
- Chiba, Yasutaka
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation